Header cover image

Hong Kong (HSI) Clinical Research and Equipment Industry Analysis

UpdatedJul 08, 2026
DataAggregated Company Financials
Companies12
  • 7D4.9%
  • 3M-4.6%
  • 1Y31.9%
  • YTDn/a

In the last week, the Clinical Research and Equipment industry is up 6.6%, with WuXi Biologics (Cayman) up 6.3%. During this same period, the InSilico Medicine Cayman TopCo underperformed, falling 9.1%. This means that the industry has gained 40% over the past year. Looking forward, earnings are forecast to grow by 35% annually.

Industry Valuation and Performance

Has the Hong Kong Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 08 Jul 2026HK$327.3bHK$48.4bHK$1.2b33.7x279.9x6.8x
Fri, 05 Jun 2026HK$295.6bHK$48.5bHK$1.2b29.3x247.4x6.1x
Sun, 03 May 2026HK$333.9bHK$48.2bHK$1.1b30.8x295.5x6.9x
Tue, 31 Mar 2026HK$316.2bHK$47.8bHK$812.9m33.6x389x6.6x
Thu, 26 Feb 2026HK$377.3bHK$43.7bHK$6.1b44.5x61.7x8.6x
Sat, 24 Jan 2026HK$389.7bHK$43.1bHK$6.0b46.3x64.8x9x
Mon, 22 Dec 2025HK$317.2bHK$42.2bHK$6.3b47.2x50.5x7.5x
Wed, 19 Nov 2025HK$314.0bHK$41.9bHK$6.2b46.5x50.5x7.5x
Fri, 17 Oct 2025HK$340.5bHK$41.8bHK$6.2b47.6x54.9x8.1x
Sun, 14 Sep 2025HK$333.4bHK$41.8bHK$6.2b47.6x53.7x8x
Tue, 12 Aug 2025HK$278.4bHK$37.2bHK$2.7b60.2x101.7x7.5x
Thu, 10 Jul 2025HK$229.2bHK$37.2bHK$2.7b44.5x83.7x6.2x
Sat, 07 Jun 2025HK$209.9bHK$36.2bHK$2.6b27.3x80.5x5.8x
Mon, 05 May 2025HK$197.2bHK$35.4bHK$2.5b27.4x77.7x5.6x
Wed, 02 Apr 2025HK$223.7bHK$35.6bHK$2.5b30.6x87.8x6.3x
Fri, 28 Feb 2025HK$199.5bHK$35.8b-HK$1,057,989,165.5654.6x-188.6x5.6x
Sun, 26 Jan 2025HK$156.5bHK$36.0b-HK$1,059,004,805.2254.6x-147.8x4.4x
Tue, 24 Dec 2024HK$157.6bHK$35.7b-HK$1,058,449,092.8060x-148.9x4.4x
Thu, 21 Nov 2024HK$139.9bHK$35.9b-HK$1,058,390,137.8544.3x-132.2x3.9x
Sat, 19 Oct 2024HK$156.8bHK$35.8b-HK$658,297,797.1024.3x-238.3x4.4x
Mon, 16 Sep 2024HK$147.3bHK$35.9b-HK$660,100,093.9524.7x-223.1x4.1x
Wed, 14 Aug 2024HK$102.7bHK$35.0bHK$2.5b17.8x41.3x2.9x
Fri, 12 Jul 2024HK$88.9bHK$33.4bHK$3.1b20.6x28.9x2.7x
Sun, 09 Jun 2024HK$89.0bHK$33.5bHK$3.1b24.4x28.8x2.7x
Tue, 07 May 2024HK$117.4bHK$33.6bHK$3.1b31.4x37.8x3.5x
Thu, 04 Apr 2024HK$115.7bHK$33.6bHK$3.1b33.5x37.3x3.4x
Sat, 02 Mar 2024HK$138.8bHK$32.3bHK$3.0b55.1x46.7x4.3x
Mon, 29 Jan 2024HK$169.8bHK$32.4bHK$3.0b69.9x56.6x5.2x
Wed, 27 Dec 2023HK$201.0bHK$32.4bHK$3.0b92.2x66.9x6.2x
Fri, 24 Nov 2023HK$294.1bHK$32.4bHK$3.0b95.8x98.1x9.1x
Sun, 22 Oct 2023HK$244.0bHK$30.1bHK$2.7b44.1x91.5x8.1x
Tue, 19 Sep 2023HK$235.7bHK$30.1bHK$2.7b41.6x88.1x7.8x
Thu, 17 Aug 2023HK$227.8bHK$28.2bHK$2.7b24.4x84.6x8.1x
Sat, 15 Jul 2023HK$217.1bHK$28.6bHK$2.8b22.7x78.6x7.6x
Price to Earnings Ratio

78.6x


Total Market Cap: HK$217.1bTotal Earnings: HK$2.8bTotal Revenue: HK$28.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Hong Kong Clinical Research and Equipment Industry Price to Earnings3Y Average 27.2x202420252026
Current Industry PE
  • Investors are optimistic on the Hong Kong Life Sciences Tools and Services industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 290x which is higher than its 3-year average PE of 27.0x.
  • The 3-year average PS ratio of 6.0x is lower than the industry's current PS ratio of 7.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have declined 25% per year over the last three years.
  • Meanwhile revenues for these companies have grown 19% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Hong Kong Clinical Research and Equipment compare with similar industries?

HK Market1.04%
Healthcare6.99%
Life Sciences4.93%
Clinical Research and Equipment4.93%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
2269 WuXi Biologics (Cayman)HK$35.663.1%
+HK$4.4b
37.7%PE25.9x
1548 Genscript BiotechHK$13.278.5%
+HK$2.3b
-13.6%PS3.9x
2268 WuXi XDC CaymanHK$58.302.2%
+HK$1.6b
34.6%PE43x
1521 Frontage HoldingsHK$1.0712.6%
+HK$243.3m
-1.8%PE40.7x
2228 XtalPi HoldingsHK$7.700.7%
+HK$215.2m
40.8%PE232x

Latest News